Thermo Fisher Scientific will make a £5 million ($7.56 million) investment in Premaitha. The company will receive £3 million ($4.53 million) at the outset with further milestone payments expected over the next two years.
This investment will enable Premaitha to offer enhanced commercial solutions to clinical laboratories across Europe and other international territories. It will also allow the company to deliver and further develop high quality, fully validated non-invasive prenatal screening tests that are designed to reduce costs and improve patient outcomes.
Premaitha’s CE-marked, non-invasive prenatal screening (NIPT) product, the IONA® test, which estimates the risk of a fetus having Down’s syndrome or other serious genetic diseases, runs on Thermo Fisher’s two sequencing instruments, the Ion Proton and Ion Chef.